Thrombus and antiplatelet therapy in type 2 diabetes mellitus: A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina

Girish N. Viswanathan, Sally M. Marshall, Clyde B. Schechter, Karthik Balasubramaniam, José J. Badimon, Azfar G. Zaman

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Type 2 diabetes mellitus (T2DM) is associated with higher rates of thrombotic complications in patients with coronary artery disease (CAD) despite optimal medical therapy. Thrombus area was measured in T2DM and non-diabetic patients receiving aspirin and clopidogrel 7-10 days after troponin positive Non ST-elevation acute coronary syndrome (NSTE-ACS). Secondly, we assessed response to clopidogrel in naive patients with T2DM and stable CAD in a randomised controlled trial. Thrombus area was measured by Badimon chamber and platelet reactivity by VerifyNow®. In T2DM patients presenting with NSTE-ACS, thrombus area was greater compared to non-diabetic patients (mean ± SD, 20,512 ± 12,567 [n=40] vs. 14,769 ± 8,531 [n=40] μm2/mm, p=0.02) Clopidogrel decreased thrombus area among stable CAD patients with T2DM (mean ± SD, Clopidogrel [n=45]: 13,978 ± 5,502 to 11,192 ± 3,764 μm 2/mm vs. placebo [n=45]: 13,959 ± 7,038 to 14,201 ± 6,780 μm 2/mm, p<0.001, delta values: clopidogrel vs. placebo, mean ± SD, 2,786 ± 4,561 vs. -249 ± 2,478, p<0.0005). Only 44% of patients with CAD and T2DM responded to clopidogrel as per VerifyNow® (cutoff PRUz value of ≥240). Importantly, no correlation was observed between thrombus area and VerifyNow® values (rho 0.08, p=0.49). Thrombus area values were similar among hypo-responders and good responders to clopidogrel (mean thrombus area ± SD: 12,186 ± 4,294 vs. 10,438 ± 3,401; p=0.17). Type 2 diabetes mellitus is associated with an increased blood thrombogenicity among NSTE-ACS patients on currently recommended medical therapy. Thrombus area was significantly reduced in all stable CAD patients independently of their response to clopidogrel therapy.

Original languageEnglish (US)
Pages (from-to)937-945
Number of pages9
JournalThrombosis and Haemostasis
Volume108
Issue number5
DOIs
StatePublished - Sep 2012

Fingerprint

clopidogrel
Stable Angina
Acute Coronary Syndrome
Type 2 Diabetes Mellitus
Thrombosis
Placebos
Prospective Studies
Coronary Artery Disease
Therapeutics
Troponin
Aspirin

Keywords

  • Acute coronary syndrome
  • Antiplatelet therapy
  • Stable coronary artery disease
  • Thrombus
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Hematology

Cite this

Thrombus and antiplatelet therapy in type 2 diabetes mellitus : A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina. / Viswanathan, Girish N.; Marshall, Sally M.; Schechter, Clyde B.; Balasubramaniam, Karthik; Badimon, José J.; Zaman, Azfar G.

In: Thrombosis and Haemostasis, Vol. 108, No. 5, 09.2012, p. 937-945.

Research output: Contribution to journalArticle

@article{d6154dbbf7434255aca23c5773abe68c,
title = "Thrombus and antiplatelet therapy in type 2 diabetes mellitus: A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina",
abstract = "Type 2 diabetes mellitus (T2DM) is associated with higher rates of thrombotic complications in patients with coronary artery disease (CAD) despite optimal medical therapy. Thrombus area was measured in T2DM and non-diabetic patients receiving aspirin and clopidogrel 7-10 days after troponin positive Non ST-elevation acute coronary syndrome (NSTE-ACS). Secondly, we assessed response to clopidogrel in naive patients with T2DM and stable CAD in a randomised controlled trial. Thrombus area was measured by Badimon chamber and platelet reactivity by VerifyNow{\circledR}. In T2DM patients presenting with NSTE-ACS, thrombus area was greater compared to non-diabetic patients (mean ± SD, 20,512 ± 12,567 [n=40] vs. 14,769 ± 8,531 [n=40] μm2/mm, p=0.02) Clopidogrel decreased thrombus area among stable CAD patients with T2DM (mean ± SD, Clopidogrel [n=45]: 13,978 ± 5,502 to 11,192 ± 3,764 μm 2/mm vs. placebo [n=45]: 13,959 ± 7,038 to 14,201 ± 6,780 μm 2/mm, p<0.001, delta values: clopidogrel vs. placebo, mean ± SD, 2,786 ± 4,561 vs. -249 ± 2,478, p<0.0005). Only 44{\%} of patients with CAD and T2DM responded to clopidogrel as per VerifyNow{\circledR} (cutoff PRUz value of ≥240). Importantly, no correlation was observed between thrombus area and VerifyNow{\circledR} values (rho 0.08, p=0.49). Thrombus area values were similar among hypo-responders and good responders to clopidogrel (mean thrombus area ± SD: 12,186 ± 4,294 vs. 10,438 ± 3,401; p=0.17). Type 2 diabetes mellitus is associated with an increased blood thrombogenicity among NSTE-ACS patients on currently recommended medical therapy. Thrombus area was significantly reduced in all stable CAD patients independently of their response to clopidogrel therapy.",
keywords = "Acute coronary syndrome, Antiplatelet therapy, Stable coronary artery disease, Thrombus, Type 2 diabetes mellitus",
author = "Viswanathan, {Girish N.} and Marshall, {Sally M.} and Schechter, {Clyde B.} and Karthik Balasubramaniam and Badimon, {Jos{\'e} J.} and Zaman, {Azfar G.}",
year = "2012",
month = "9",
doi = "10.1160/TH12-06-0408",
language = "English (US)",
volume = "108",
pages = "937--945",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "5",

}

TY - JOUR

T1 - Thrombus and antiplatelet therapy in type 2 diabetes mellitus

T2 - A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina

AU - Viswanathan, Girish N.

AU - Marshall, Sally M.

AU - Schechter, Clyde B.

AU - Balasubramaniam, Karthik

AU - Badimon, José J.

AU - Zaman, Azfar G.

PY - 2012/9

Y1 - 2012/9

N2 - Type 2 diabetes mellitus (T2DM) is associated with higher rates of thrombotic complications in patients with coronary artery disease (CAD) despite optimal medical therapy. Thrombus area was measured in T2DM and non-diabetic patients receiving aspirin and clopidogrel 7-10 days after troponin positive Non ST-elevation acute coronary syndrome (NSTE-ACS). Secondly, we assessed response to clopidogrel in naive patients with T2DM and stable CAD in a randomised controlled trial. Thrombus area was measured by Badimon chamber and platelet reactivity by VerifyNow®. In T2DM patients presenting with NSTE-ACS, thrombus area was greater compared to non-diabetic patients (mean ± SD, 20,512 ± 12,567 [n=40] vs. 14,769 ± 8,531 [n=40] μm2/mm, p=0.02) Clopidogrel decreased thrombus area among stable CAD patients with T2DM (mean ± SD, Clopidogrel [n=45]: 13,978 ± 5,502 to 11,192 ± 3,764 μm 2/mm vs. placebo [n=45]: 13,959 ± 7,038 to 14,201 ± 6,780 μm 2/mm, p<0.001, delta values: clopidogrel vs. placebo, mean ± SD, 2,786 ± 4,561 vs. -249 ± 2,478, p<0.0005). Only 44% of patients with CAD and T2DM responded to clopidogrel as per VerifyNow® (cutoff PRUz value of ≥240). Importantly, no correlation was observed between thrombus area and VerifyNow® values (rho 0.08, p=0.49). Thrombus area values were similar among hypo-responders and good responders to clopidogrel (mean thrombus area ± SD: 12,186 ± 4,294 vs. 10,438 ± 3,401; p=0.17). Type 2 diabetes mellitus is associated with an increased blood thrombogenicity among NSTE-ACS patients on currently recommended medical therapy. Thrombus area was significantly reduced in all stable CAD patients independently of their response to clopidogrel therapy.

AB - Type 2 diabetes mellitus (T2DM) is associated with higher rates of thrombotic complications in patients with coronary artery disease (CAD) despite optimal medical therapy. Thrombus area was measured in T2DM and non-diabetic patients receiving aspirin and clopidogrel 7-10 days after troponin positive Non ST-elevation acute coronary syndrome (NSTE-ACS). Secondly, we assessed response to clopidogrel in naive patients with T2DM and stable CAD in a randomised controlled trial. Thrombus area was measured by Badimon chamber and platelet reactivity by VerifyNow®. In T2DM patients presenting with NSTE-ACS, thrombus area was greater compared to non-diabetic patients (mean ± SD, 20,512 ± 12,567 [n=40] vs. 14,769 ± 8,531 [n=40] μm2/mm, p=0.02) Clopidogrel decreased thrombus area among stable CAD patients with T2DM (mean ± SD, Clopidogrel [n=45]: 13,978 ± 5,502 to 11,192 ± 3,764 μm 2/mm vs. placebo [n=45]: 13,959 ± 7,038 to 14,201 ± 6,780 μm 2/mm, p<0.001, delta values: clopidogrel vs. placebo, mean ± SD, 2,786 ± 4,561 vs. -249 ± 2,478, p<0.0005). Only 44% of patients with CAD and T2DM responded to clopidogrel as per VerifyNow® (cutoff PRUz value of ≥240). Importantly, no correlation was observed between thrombus area and VerifyNow® values (rho 0.08, p=0.49). Thrombus area values were similar among hypo-responders and good responders to clopidogrel (mean thrombus area ± SD: 12,186 ± 4,294 vs. 10,438 ± 3,401; p=0.17). Type 2 diabetes mellitus is associated with an increased blood thrombogenicity among NSTE-ACS patients on currently recommended medical therapy. Thrombus area was significantly reduced in all stable CAD patients independently of their response to clopidogrel therapy.

KW - Acute coronary syndrome

KW - Antiplatelet therapy

KW - Stable coronary artery disease

KW - Thrombus

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84870361887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870361887&partnerID=8YFLogxK

U2 - 10.1160/TH12-06-0408

DO - 10.1160/TH12-06-0408

M3 - Article

C2 - 23015113

AN - SCOPUS:84870361887

VL - 108

SP - 937

EP - 945

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 5

ER -